Welcome to our dedicated page for EDVA news (Ticker: EDVA), a resource for investors and traders seeking the latest updates and insights on EDVA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EDVA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EDVA's position in the market.
Endovia Health Sciences (NYSE American: EDVA), formerly Splash Beverage (SBEV), announced that the FDA Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No. 14145 for its CannEpil® veterinary development program. This is the first regulatory milestone under Endovia Health’s collaboration with Lupvindol Biosciences and formally begins FDA regulatory engagement for CannEpil as an investigational veterinary pharmaceutical.
Endovia Health is initially targeting cancer‑related pain in canine oncology and plans to pursue the FDA’s Minor Use / Minor Species (MUMS) designation and Conditional Approval pathway. According to the company, Splash holds exclusive global rights to develop and commercialize CannEpil, and the business has rebranded to reflect a diversified cannabinoid‑based health sciences platform.